We conduct a multi-institutional randomized control trial of RFA and MWA for the primary treatment of large, benign nodules. Adult patients \>/=18 years of age who have a solitary thyroid nodule ≥20ml in volume who presents to 1) Columbia University, NY or 2) Queen Mary Hospital, Hong Kong for consultation will be eligible for enrollment in the study. They will need either a) two benign fine needle biopsies, with the most recent biopsy performed within 1 year of enrollment in study or b) one benign fine needle biopsy and low suspicion characteristics on ultrasound. Both functional and non-functional nodules are eligible. Patients will be randomly assigned to either treatment arm a) RFA or treatment arm b) MWA according to a pre-generated block randomization list.
Benign thyroid nodules can cause compressive symptoms for patients, including neck pressure and discomfort, dysphagia, dyspnea, and dysphonia. Some nodules will become autonomously functioning causing hyperthyroidism. Traditionally the gold standard treatment for these benign, but problematic nodules, has been thyroidectomy. Although generally a low risk operation, thyroidectomy is associated with some risk for recurrent laryngeal nerve injury, bleeding, infection, and need for thyroid hormone supplementation. Introduced in the early 2000s, ultrasound-guided percutaneous ablation of thyroid lesions has emerged as a potential alternative to surgery in patients with benign thyroid nodules. Of the myriad ablation methods, the most commonly used technique are radiofrequency ablation (RFA) and microwave ablation (MWA). The two techniques used different mechanisms for heat generation. Current evidence comparing RFA versus MWA for thyroid ablation were limited and were either retrospective or non-randomized, with focus mainly on small thyroid nodules of ≤10ml in volume. There is a lack of high quality evidence on the safety and efficacy of RFA versus MWA for the treatment of large thyroid nodules (≥20ml). The aim of this randomized controlled trial is to compare the safety and efficacy of RFA and MWA in the treatment of large, benign thyroid nodules. The primary outcome of is the volume reduction rate at 6 months after ablation. The secondary outcomes include safety, complication rates and quality of life after both procedures.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Ultrasound-guided thermal ablation will be performed using STARmed internally cooled RFA electrodes (18 gauge) powered by the VIVA RF generator in accordance with the trans-isthmic 'moving shot' technique.
Ultrasound-guided thermal ablation will be performed using ECO Medical internally cooled MWA antennas (16 or 17 gauge) powered by the ECO Medical generator in accordance with the trans-isthmic 'moving shot' technique.
Queen Mary Hospital
Hong Kong, Hong Kong
Volume reduction rate (VRR) of thyroid nodule at 6 months (%)
To measure the volume reduction rate (VRR) of thyroid nodule at 6-month. volume of nodule= length(cm) x width(cm) x depth(cm) x (π / 6 ) VRR = \[(volume at baseline - volume at 6-month)/volume of baseline\] x 100%
Time frame: 6 months
Volume reduction rate (VRR) of thyroid nodule at 12 months (%)
To measure the volume reduction rate (VRR) of thyroid nodule at 12-month. volume of nodule= length(cm) x width(cm) x depth(cm) x (π / 6 ) VRR = \[(volume at baseline - volume at 12-m / Volume at baseline\] x 100%
Time frame: 12-months
Changes in compressive symptom scores (0-100)
To measure the changes in compressive symptoms scores. Compressive symptoms score is from 0 to 100. The higher score means more compressive symptom.
Time frame: 12 months
Changes in cosmetic symptom scores (1-4)
To assess the change of cosmetic symptom by experienced doctors until 12 months. Cosmetic symptoms is from 1 to 4 as below 1. = no palpable goitre 2. = Palpable goiter but invisible 3. = Goitre only visible to experienced clinician 4. = Easily visible goitre
Time frame: 12 months
Peri-operative pain scores (0-10)
To measure the change in pain score before and after ablation. The pain score is from 0 to 10, the higher score means more painful.
Time frame: 12 months
Complications from procedure including vocal cord palsy, bleeding, infection, nodule rupture, skin burn
Description: To assess for any complications arising from procedure during follow-up period after ablation
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.